
Lexaria Bioscience Corp. Warrant
LEXXW
LEXXW: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.
moreShow LEXXW Financials
Recent trades of LEXXW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LEXXW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on LEXXW's company Twitter account
Number of mentions of LEXXW in WallStreetBets Daily Discussion
Recent insights relating to LEXXW
Recent picks made for LEXXW stock on CNBC
ETFs with the largest estimated holdings in LEXXW
Flights by private jets registered to LEXXW